Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will have discussions with NICE on the potential merits of offering Givinostat for Duchenne muscular dystrophy.

There are no plans to have discussions with the National Institute for Health and Care Excellence (NICE) on offering givinostat for Duchenne muscular dystrophy. The NICE makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS independently, based on an assessment of their costs and benefits. The NHS in England is legally required to fund medicines recommended by the NICE, normally within three months of the publication of final guidance. The NICE is currently evaluating givinostat, and its Appraisal Committee will meet to consider its recommendations in May 2025.